Centogene N.V. - Common Shares (CNTG)
CNTG moved a median of -1.82% 30 minutes after news, and -1.22% by the close. How CNTG actually reacts to news — the realized, point-in-time move the market made, measured across 58 labeled events over the last three years with zero look-ahead.
CNTG’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 12% | 41 |
| 30-min | -1.82% | 18% | 44 |
| 60-min | -2.39% | 10% | 48 |
| to close | -1.22% | 43% | 51 |
| Middle 50% of CNTG reactions | -5.02% to 0.00% |
|---|---|
| Median reaction (30-min) | -1.82% |
| Measured reactions | 58 |
Half of all Centogene N.V. - Common Shares news events land between -5.02% and +0.00% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when CNTG moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CNTG's baseline. Nothing else.
Recent CNTG events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| CENTOGENE Closes Strategic Transaction with Private Equity Group Charme Capital Partners | Press release | GlobeNewswire | — | — | |
| CENTOGENE Announces Voting Results of Extraordinary General Meeting | Press release | GlobeNewswire | — | — | |
| CENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners | Press release | GlobeNewswire | — | — | |
| CENTOGENE Data on Novel Genetic Risk Factor for Parkinson’s Disease in The Lancet Neurology | Press release | GlobeNewswire | — | — | |
| Form 6-K Centogene N.V. For: Aug 19 | SEC filing · Form 6-K | SEC EDGAR | — | — | |
| Form 6-K Centogene N.V. For: Aug 07 | SEC filing · Form 6-K | SEC EDGAR | — | — | |
| CENTOGENE Receives Delisting Notice From Nasdaq | Press release | GlobeNewswire | — | — | |
| CENTOGENE Publication in Brain Journal Reveals 15% of Parkinson’s Disease Cases Are Linked to Genetic Factors | Press release | GlobeNewswire | +0.00% | -3.89% | |
| Form 6-K Centogene N.V. For: Aug 01 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -3.89% | |
| C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development | Press release | GlobeNewswire | +2.39% | -1.22% | |
| Form 6-K Centogene N.V. For: Jun 20 | SEC filing · Form 6-K | SEC EDGAR | +2.39% | -1.22% | |
| CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting | Press release | GlobeNewswire | -1.82% | +0.21% | |
| Form 6-K Centogene N.V. For: May 31 | SEC filing · Form 6-K | SEC EDGAR | -1.82% | +0.21% | |
| Form 6-K Centogene N.V. For: May 29 | SEC filing · Form 6-K | SEC EDGAR | — | -4.38% | |
| Form IRANNOTICE Centogene N.V. | SEC filing · Form IRANNOTICE | SEC EDGAR | -3.64% | -3.90% | |
| CENTOGENE Reports Full Year 2023 Financial Results and Recent Business Highlights | Press release | GlobeNewswire | -7.80% | -24.00% | |
| CENTOGENE Secures Approx. $20 Million to Strengthen Cash Position | Press release | GlobeNewswire | -7.80% | -24.00% | |
| Form 20-F Centogene N.V. For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | -7.80% | -24.00% | |
| Form 6-K Centogene N.V. For: May 15 | SEC filing · Form 6-K | SEC EDGAR | -7.80% | -24.00% | |
| CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease | Press release | GlobeNewswire | +0.00% | +5.03% | |
| Form 6-K Centogene N.V. For: May 14 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +5.03% | |
| CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients | Press release | GlobeNewswire | — | +2.36% | |
| Form 6-K Centogene N.V. For: May 10 | SEC filing · Form 6-K | SEC EDGAR | — | +2.36% | |
| Form 6-K Centogene N.V. For: May 01 | SEC filing · Form 6-K | SEC EDGAR | — | -1.79% | |
| Form NT 20-F Centogene N.V. For: Dec 31 | SEC filing · Form NT | SEC EDGAR | — | -1.79% | |
| CENTOGENE Receives Nasdaq Non-Compliance Notice | Press release | GlobeNewswire | +0.00% | -1.40% | |
| Form 6-K Centogene N.V. For: Apr 02 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -1.40% | |
| CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders | Press release | GlobeNewswire | -1.41% | -1.41% | |
| Form 6-K Centogene N.V. For: Mar 19 | SEC filing · Form 6-K | SEC EDGAR | -1.41% | -1.41% | |
| CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRa Deficiency | Press release | GlobeNewswire | +0.00% | +11.11% | |
| Form 6-K Centogene N.V. For: Feb 29 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +11.11% | |
| CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing | Press release | GlobeNewswire | -5.00% | -2.64% | |
| CENTOGENE Explores Strategic Alternatives | Press release | GlobeNewswire | -5.00% | -2.64% | |
| Form 6-K Centogene N.V. For: Feb 28 | SEC filing · Form 6-K | SEC EDGAR | -5.00% | -2.64% | |
| CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration | Press release | GlobeNewswire | — | -1.68% | |
| Form 6-K Centogene N.V. For: Jan 25 | SEC filing · Form 6-K | SEC EDGAR | — | -1.68% | |
| CENTOGENE Receives French Research Tax Credit Accreditation | Press release | GlobeNewswire | +0.00% | -1.64% | |
| Form 6-K Centogene N.V. For: Jan 24 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -1.64% | |
| CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics | Press release | GlobeNewswire | -0.02% | +0.00% | |
| Form 6-K Centogene N.V. For: Jan 23 | SEC filing · Form 6-K | SEC EDGAR | -0.02% | +0.00% | |
| CENTOGENE Announces Preliminary Full Year 2023 Revenue | Press release | GlobeNewswire | -3.31% | +3.31% | |
| Form 6-K Centogene N.V. For: Jan 18 | SEC filing · Form 6-K | SEC EDGAR | -3.31% | +3.31% | |
| CENTOGENE Announces Voting Results of Extraordinary General Meeting | Press release | GlobeNewswire | +0.00% | +6.14% | |
| Form 6-K Centogene N.V. For: Dec 18 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +6.14% | |
| Form 6-K Centogene N.V. For: Dec 18 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +0.87% | |
| CENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone | Press release | GlobeNewswire | -1.63% | +1.63% | |
| Form 6-K Centogene N.V. For: Dec 13 | SEC filing · Form 6-K | SEC EDGAR | -1.63% | +1.63% | |
| Form 6-K Centogene N.V. For: Dec 01 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -2.38% | |
| CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture Transaction | Press release | GlobeNewswire | +0.77% | +0.77% | |
| Form 6-K Centogene N.V. For: Nov 28 | SEC filing · Form 6-K | SEC EDGAR | +0.77% | +0.77% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CNTG section they belong to.
Where else CNTG is measured.
CNTG earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Centogene N.V. - Common Shares's median reaction calculated?
Every labeled CNTG news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 58 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 18% of CNTG's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CNTG's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.